Trials / Terminated
TerminatedNCT03476928
A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding
An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 153 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of vilaprisan in Japanese subjects with uterine fibroids and heavy menstrual bleeding (HMB).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vilaprisan (BAY1002670) | 2mg, once daily, oral |
Timeline
- Start date
- 2018-03-30
- Primary completion
- 2021-07-12
- Completion
- 2021-07-12
- First posted
- 2018-03-26
- Last updated
- 2022-07-08
Locations
25 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03476928. Inclusion in this directory is not an endorsement.